Document:

exv10w1

Exhibit 10.1

CONTINGENT VALUE RIGHTS AGREEMENT

     THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of August 12, 2010 (this
“Agreement”), is entered into by and among Emergent BioSolutions Inc., a Delaware
corporation (“Parent”), Trubion Pharmaceuticals, Inc., a Delaware corporation
(“Company”), and Mellon Investor Services LLC, a New Jersey limited liability company, as
Rights Agent (the “Rights Agent”) and as initial CVR Registrar (as defined herein).

RECITALS

     A. Parent, 35406 LLC, a Delaware limited liability company and wholly owned direct subsidiary
of Parent (the “LLC”), 30333 Inc, a Delaware corporation and wholly owned indirect
subsidiary of Parent (“Merger Sub”), and Company have entered into an Agreement and Plan of
Merger dated as of August 12, 2010 (the “Merger Agreement”), pursuant to which the Merger
Sub will merge (the “Merger”) with and into the Company, with the Company surviving the
Merger as an indirect subsidiary of Parent, and then merging with and into the LLC with the LLC
being the surviving entity of the LLC Merger.

     B. Pursuant to the Merger Agreement, Parent agreed to grant to the Company’s stockholders of
record immediately prior to the Effective Time contingent value rights as hereinafter described.

     C. The parties have done all things necessary to make the contingent value rights, when
granted pursuant to the Merger Agreement and hereunder, the valid obligations of Parent and to make
this Agreement a valid and binding agreement of Parent, in accordance with its terms.

AGREEMENT

     In consideration of the premises and the consummation of the transactions referred to above,
it is mutually covenanted and agreed, for the equal and proportionate benefit of all Holders (as
hereinafter defined), as follows:

ARTICLE I

DEFINITIONS

Section 1.1 Definitions.

     (a) For all purposes of this Agreement, except as otherwise expressly provided or unless the
context otherwise requires:

 

 

          (i) the terms defined in this Article have the meanings assigned to them in this Article, and
include the plural as well as the singular;

          (ii) all accounting terms used herein and not expressly defined herein shall have the meanings
assigned to such terms in accordance with U.S. generally accepted accounting principles, as in
effect on the date hereof;

          (iii) the words “herein,” “hereof” and “hereunder” and other words of similar import refer to
this Agreement as a whole and not to any particular Article, Section or other subdivision;

          (iv) unless the context otherwise requires, words describing the singular number shall include
the plural and vice versa, words denoting any gender shall include all genders and words denoting
natural Persons shall include corporations, partnerships and other Persons and vice versa; and

          (v) all references to “including” shall be deemed to mean including without limitation.

     (b) Capitalized terms used but not otherwise defined herein shall have the meanings ascribed
thereto in the Merger Agreement. The following terms shall have the meanings ascribed to them as
follows:

“Applicable Payments” means the amount payable in cash with respect to a particular
CVR Payment Event, as set forth on Annex A.

“Board of Directors” means the board of directors of Parent.

“Board Resolution” means a copy of a resolution certified by the secretary or an
assistant secretary of Parent to have been duly adopted by the Board of Directors and to be
in full force and effect on the date of such certification, and delivered to the Rights
Agent.

“Business Day” means any day other than a Saturday, Sunday or a day on which banking
institutions in Seattle, Washington or in the states of New York and New Jersey are
authorized or obligated by law or executive order to remain closed.

“CVR” means the contingent value rights granted by Parent pursuant to the Merger
Agreement and this Agreement.

“CVR Achievement Period” means the period commencing upon the Effective Time and
ending on the third anniversary of the Effective Time.

“CVR Payment Amount” means an amount resulting from dividing each Applicable Payment
by the total number of outstanding CVRs.

“CVR Payment Certificate” has the meaning set forth in Section 2.5(a).

2

 

“CVR Payment Date” means the date specified by Parent on which a CVR Payment Amount
is to be paid by the Rights Agent to the Holders, which date shall be a date no later than
ten (10) days after the applicable CVR Payment Event and shall be established pursuant to
Section 2.5.

“CVR Payment Event” means, as applicable, (a) the receipt by Parent (or its
successors or assigns) of a Milestone Payment related to a Milestone Achievement Event that
occurred during the CVR Achievement Period or (b) the Achievement Event under the Facet
Agreement as set forth and described on Annex A.

“CVR Register” has the meaning set forth in Section 2.3(b).

“CVR Registrar” has the meaning set forth in Section 2.3(b).

“Facet Agreement” means the Collaboration and License Agreement between the Company
and Facet Biotech Corporation, dated August 27, 2009.

“Holder” means a Person in whose name a CVR is registered in the CVR Register.

“Milestone Achievement Certificate” has the meaning set forth in Section
2.4(a).

“Milestone Achievement Event” means the achievement of a Milestone Event.

“Milestone Event” means the milestone events under the Wyeth Agreement and the Facet
Agreement set forth on Annex A.

“Milestone Payment” means the milestone payments associated with the Milestone
Events.

“Milestone Payment Failure” has the meaning set forth in Section 2.4(c).

“Milestone Payment Failure Notice” has the meaning set forth in Section
2.4(c).

“Non-Achievement Certificate” has the meaning set forth in Section 4.3(a).

“Notice of Objection” has the meaning set forth in Section 4.3(b).

“Objection Period” has the meaning set forth in Section 4.3(b).

“Officer’s Certificate” means a certificate signed by the chief executive officer,
president, chief financial officer, or the secretary, in each case of Parent, in his or her
capacity as such an officer, and delivered to the Rights Agent.

“Permitted Transfer” means: (i) the transfer of any or all of the CVRs on death by
will or intestacy; (ii) transfer by instrument to an inter vivos or testamentary trust in
which the CVRs are to be passed to beneficiaries upon the death of the trustee; (iii)
transfers made pursuant to a court order; or (iv) a transfer made by operation of law
(including a consolidation or merger) or in connection with the dissolution, liquidation or
termination of any corporation, limited liability company, partnership or other entity.

3

 

“Person” means any individual, firm, corporation, limited liability company,
partnership, trust or other entity, and shall include any successor (by merger or otherwise)
thereof or thereto.

“Rights Agent” means the Rights Agent named in the first paragraph of this
Agreement, until a successor Rights Agent shall have become such pursuant to the applicable
provisions of this Agreement, and thereafter “Rights Agent” shall mean such successor Rights
Agent.

“Surviving Person” has the meaning set forth in Section 6.1(a).

“Wyeth Agreement” means the Collaboration and License Agreement between the Company
and Wyeth, acting through Wyeth Pharmaceuticals Division, dated December 19, 2005, as
amended.

“20% Holders” means any Holder or Holders of at least twenty percent (20%) in the
aggregate of the outstanding CVRs.

ARTICLE II

CONTINGENT VALUE RIGHTS

Section 2.1 Grant of CVRs.

     The CVRs shall be granted pursuant to, and at the time and in the manner set forth in, the
Merger Agreement and shall thereafter be governed and administered in accordance with this
Agreement. Parent hereby appoints Mellon Investor Services LLC as the Rights Agent to act as
rights agent for the Parent in accordance with the express terms and conditions set forth in this
Agreement (and no implied terms or conditions), and the Rights Agent hereby accepts such
appointment.

Section 2.2 Nontransferable.

     The CVRs shall not be sold, assigned, transferred, pledged, encumbered or in any other manner
transferred or disposed of, in whole or in part, other than through a Permitted Transfer.

Section 2.3 No Certificate; Registration; Registration of Transfer; Change of Address.

     (a) The CVRs shall not be evidenced by a certificate or other instrument.

     (b) The Rights Agent shall keep a register (the “CVR Register”) for the registration
of CVRs. The Rights Agent is hereby initially appointed “CVR Registrar” for the purpose of
registering CVRs and transfers of CVRs as herein provided.

     (c) Subject to the restriction on transferability set forth in Section 2.2, every
request made to transfer a CVR must be in writing and accompanied by a written instrument of
transfer and any other documentation reasonably requested by the CVR Registrar, in a form
reasonably satisfactory to the CVR Registrar, properly completed and duly executed by the Holder
thereof,

4

 

his attorney duly authorized in writing, personal representative or survivor and setting forth
in reasonable detail the circumstances relating to the transfer, and such signature to be
guaranteed by a participant in a recognized Signature Guarantee Medallion Program. Upon receipt of
such written notice and all other necessary information, the CVR Registrar shall, register the
transfer of the CVRs in the CVR Register. All duly transferred CVRs registered in the CVR Register
shall be the valid obligations of Parent, evidencing the same right, and shall entitle the
transferee to the same benefits and rights under this Agreement, as those held by the transferor.
No transfer of a CVR shall be valid until registered in the CVR Register, and any transfer not duly
registered in the CVR Register will be void ab initio. Any transfer or assignment of the CVRs
shall be without charge (other than the cost of any transfer tax or other governmental charge that
may be payable in respect of such transfer or assignment, which shall be the responsibility of the
transferor) to the Holder. The Rights Agent shall have no duty or obligation under any Section of
this Agreement that requires the payment of taxes or charges unless and until it is satisfied that
such taxes and/or charges have been paid.

     (d) A Holder may make a written request to the CVR Registrar to change such Holder’s address
of record in the CVR Register. The written request must be duly executed by the Holder. Upon
receipt of such written notice, the CVR Registrar shall promptly record the change of address in
the CVR Register.

Section 2.4 Milestone Achievement Procedures; Payment Failure.

     (a) Following the occurrence of a Milestone Achievement Event, Parent shall promptly, but in
no event later than five (5) Business Days after such event, deliver to the Rights Agent an
Officer’s Certificate certifying that the Parent is entitled to receive the applicable Milestone
Payment (the “Milestone Achievement Certificate”).

     (b) Subsequent to the occurrence of any Milestone Achievement Event, Parent shall use
commercially reasonable efforts to cause the counterparty to the Facet Agreement or the Wyeth
Agreement, as applicable, to promptly remit the applicable Milestone Payment to the Parent in
accordance with the Facet Agreement or the Wyeth Agreement, as applicable, and the Parent shall
thereafter disburse the Applicable Payment in accordance with Section 2.5.

     (c) In the event that the applicable Milestone Payment has not been made in accordance with
and during the timeframes provided for in the Facet Agreement or the Wyeth Agreement, as the case
may be (a “Milestone Payment Failure”), the Parent shall deliver to the Rights Agent a
notice signed by the chief executive officer, president or chief financial officer of Parent
notifying the Rights Agent of the Milestone Payment Failure (the “Milestone Payment Failure
Notice”). The Rights Agent shall forward any Milestone Payment Failure Notice it receives to
the Holders within five (5) Business Days of receipt. Any dispute arising from a Milestone Payment
Failure Notice shall be resolved in accordance with the procedure set forth in Section
7.10, which decision shall be binding on the parties hereto and the Holders (including the
Holders not participating therein).

5

 

Section 2.5 Payment Procedures.

     (a) Upon an occurrence of a CVR Payment Event, Parent shall promptly, but in no event later
than five (5) Business Days thereafter, deliver to the Rights Agent an Officer’s Certificate
certifying that each Holder is entitled to receive the CVR Payment Amount (the “CVR Payment
Certificate”), which shall set forth the CVR Payment Date. The Rights Agent shall forward any
CVR Payment Certificate it receives to the Holders within five (5) Business Days of receipt. Until
such CVR Payment Certificate is received by the Rights Agent, the Rights Agent may presume
conclusively for all purposes that a CVR Payment Event has not occurred.

     (b) At least five (5) Business Days prior to the applicable CVR Payment Date, Parent shall
cause the Applicable Payment to be delivered to the Rights Agent, who will in turn, on the CVR
Payment Date, pay the applicable CVR Payment Amount to each of the Holders (the amount which each
Holder is entitled to receive will be based on the number of CVRs held by such Holder as reflected
on the CVR Register) (i) by check mailed to the address of each Holder as reflected in the CVR
Register as of the close of business on the last Business Day prior to such CVR Payment Date, or,
(ii) with respect to Holders that are due CVR Payment Amounts in excess of $100,000 who have
provided the Rights Agent with wire transfer instructions in writing, by wire transfer of
immediately available funds to such account. The Rights Agent shall have no duty or obligation to
verify or confirm the accuracy, validity or sufficiency of the applicable CVR Payment Amount.

     (c) Parent shall be entitled to deduct and withhold, or cause to be deducted or withheld, from
each CVR Payment Amount otherwise payable pursuant to this Agreement, such amounts as it is
required to deduct and withhold with respect to the making of such payment under the Code, or any
provision of state, local or foreign tax Law. To the extent that amounts are so withheld or paid
over to or deposited with the relevant Governmental Entity, such withheld amounts shall be treated
for all purposes of this Agreement as having been paid to the Holder in respect of which such
deduction and withholding was made.

	 	 	Section 2.6 No Voting, Dividends Or Interest; No Equity Or Ownership Interest In Parent.

     (a) The CVRs shall not have any voting or dividend rights, and interest shall not accrue on
any amounts payable on the CVRs to any Holder.

     (b) The CVRs shall not represent any equity or ownership interest in Parent or in any
constituent company to the Integrated Merger.

ARTICLE III

THE RIGHTS AGENT

Section 3.1 Certain Duties And Responsibilities.

     The Rights Agent shall be authorized and protected and shall not have any liability for, or in
respect of any actions taken, suffered or omitted to be taken by it in connection with its
acceptance and administration of this Agreement and the exercise and performance of its duties

6

 

hereunder, except to the extent of its own willful misconduct, bad faith or gross negligence
(each as determined by a final, non-appealable judgment of a court of competent jurisdiction).
Anything to the contrary notwithstanding, in no event shall the Rights Agent be liable for any
special, punitive, indirect, consequential or incidental loss or damage of any kind whatsoever
(including but not limited to lost profits), even if the Rights Agent has been advised of the
likelihood of such loss or damage. Any liability of the Rights Agent will be limited to the amount
of annual fees paid by the Buyer to the Rights Agent. No provision of this Agreement shall require
the Rights Agent to expend or risk its own funds or otherwise incur any financial liability in the
performance of any of its duties hereunder or in the exercise of any of its rights or powers.

Section 3.2 Certain Rights of Rights Agent.

     The Rights Agent undertakes to perform such duties and only such duties as are specifically
set forth in this Agreement, and no implied covenants or obligations shall be read into this
Agreement against the Rights Agent. In addition:

     (a) the Rights Agent may rely and shall be authorized and protected in acting or refraining
from acting upon any resolution, certificate, statement, instrument, opinion, report, notice,
request, direction, consent, order, power of attorney, endorsement, affidavit, letter or other
paper or document believed by it to be genuine and to have been signed or presented by the proper
party or parties. The Rights Agent shall not be deemed to have knowledge of any event of which it
was supposed to receive notice thereof hereunder but as to which no notice was provided, and the
Rights Agent shall be fully protected and shall incur no liability for failing to take any action
in connection therewith unless and until it has received such notice;

     (b) whenever the Rights Agent shall deem it necessary or desirable that any fact or matter be
proved or established by the Buyer prior to taking, suffering or omitting to take any action
hereunder, the Rights Agent may, in the absence of bad faith, gross negligence or willful
misconduct on its part (each as determined by a final, non-appealable judgment of a court of
competent jurisdiction), request and rely upon an Officer’s Certificate from the Parent
with respect to such fact or matter; and such certificate shall be full and complete
authorization and protection to the Rights Agent and the Rights Agent shall incur no liability for
or in respect of any action taken, suffered or omitted to be taken by it under the provisions of
this Agreement in reliance upon such certificate. The Rights Agent shall be fully authorized and
protected in relying upon the most recent instructions received from Parent. In the event the
Rights Agent believes any ambiguity or uncertainty exists hereunder or in any notice, instruction,
direction, request or other communication, paper or document received by the Rights Agent
hereunder, the Rights Agent, may, in its sole discretion, refrain from taking any action, and shall
be fully protected and shall not be liable in any way to Parent or any other person or entity for
refraining from taking such action, unless the Rights Agent receives written instructions from
Parent that eliminates such ambiguity or uncertainty to the satisfaction of the Rights Agent;

     (c) the Rights Agent may engage and consult with counsel of its selection (who may be legal
counsel for the Buyer and/or an employee of the Rights Agent) and the advice of such counsel or any
opinion of counsel shall be full and complete authorization and protection to the

7

 

Rights Agent in respect of any action taken, suffered or omitted to be taken by it hereunder
in reliance thereon;

     (d) in the event of litigation, the Rights Agent may engage and consult with tax experts,
valuation firms and other experts and third parties that it, in its sole and absolute discretion,
deems appropriate or necessary to enable it to discharge its duties hereunder;

     (e) the permissive rights of the Rights Agent to do things enumerated in this Agreement shall
not be construed as a duty;

     (f) the Rights Agent shall not be required to give any note or surety in respect of the
execution of such powers or otherwise in respect of the premises;

     (g) Parent agrees to indemnify Rights Agent for, and hold Rights Agent harmless against, any
loss, liability, claim, demands, suits, damage, judgment, fine, penalty, settlement, cost or
expense (including, without limitation, the fees and expenses of legal counsel), incurred without
willful misconduct, bad faith or gross negligence on the part of the Rights Agent (each as
determined by a final non-appealable judgment of a court of competent jurisdiction) for any action
taken, suffered or omitted to be taken by the Rights Agent in connection with the acceptance and
administration of this Agreement, or the exercise or performance of its duties hereunder, including
without limitation, the costs and expense of defending against any claim of liability hereunder,
directly or indirectly. The costs and expenses incurred in enforcing this right of indemnification
shall be paid by the Parent. The provisions of this Article 3 shall survive the termination of this
Agreement, the payment of any distributions made pursuant to this Agreement, and the resignation,
replacement or removal of the Rights Agent hereunder, including, without limitation, the costs and
expenses of defending a claim of liability hereunder;

     (h) Parent agrees (i) to pay the fees and expenses of the Rights Agent in connection with this
Agreement, as set forth on Schedule 1 hereto, and (ii) to reimburse the Rights Agent for
all taxes and governmental charges, reasonable expenses and other charges of any kind and nature
incurred by the Rights Agent in the execution of this Agreement (other than taxes measured by the
Rights Agent’s net income). The Rights Agent shall also be entitled to reimbursement from Parent
for all reasonable and necessary out-of-pocket expenses paid or incurred by it in connection with
the preparation, negotiation, delivery, amendment, administration and execution by the Rights Agent
of this Agreement and its duties hereunder. An invoice for any out-of-pocket expenses and per item
fees realized will be rendered and payable within thirty (30) days after receipt by Parent, except
for postage and mailing expenses, which funds must be received one Business Day prior to the
scheduled mailing date. Parent agrees to pay to the Rights Agent any amounts, including fees and
expenses, payable in favor of the Rights Agent in connection with any dispute arising under or in
connection with this Agreement;

     (i) The Rights Agent shall not be liable for or by reason of any of the statements of fact or
recitals contained in this Agreement or be required to verify the same, but all such statements and
recitals are and shall be deemed to have been made by Parent only;

8

 

     (j) The Rights Agent shall not have any liability for or be under any responsibility in
respect of the validity of this Agreement or the execution and delivery hereof; nor shall it be
responsible for any breach by Parent of any covenant or failure by Parent to satisfy conditions
contained in this Agreement;

     (k) Parent agrees that it will perform, execute, acknowledge and deliver or cause to be
performed, executed, acknowledged and delivered all such further and other acts, instruments and
assurances as may reasonably be required by the Rights Agent for the carrying out or performing by
the Rights Agent of its duties under this Agreement;

     (l) The Rights Agent and any stockholder, affiliate, director, officer, employee or agent of
the Rights Agent may buy, sell or deal in any of the Rights or other securities of Parent or become
pecuniarily interested in any transaction in which Parent may be interested, or contract with or
lend money to Parent or otherwise act as fully and freely as though it were not Rights Agent under
this Agreement. Nothing herein shall preclude the Rights Agent or any stockholder, affiliate,
director, officer, employee or agent from acting in any other capacity for Parent or for any other
Person; and

     (m) The Rights Agent shall not be subject to, nor be required to comply with, or determine if
any person or entity has complied with, the Merger Agreement or any other agreement between or
among any of Parent, Company or any other parties hereto, even though reference thereto may be made
in this Agreement, or to comply with any notice, instruction, direction, request or other
communication, paper or document other than as expressly set forth in this Agreement

     (n) The Rights Agent shall not incur any liability for not performing any act, duty,
obligation or responsibility by reason of any occurrence beyond the control of the Rights Agent
(including, without limitation , any act or provision of any present or future law or regulation or
governmental authority, any act of God, war, civil disorder or failure of any means of
communication); and

     (o) The Rights Agent may execute and exercise any of the rights of powers hereby vested in it
or perform any duty hereunder either itself (through its directors, officers or employees) or by or
through its attorneys or agents, and the Rights Agent shall not be answerable or accountable for
any act, omission, default, neglect or misconduct of any such attorneys or agents or for any loss
to Parent or any other Person resulting from any such act, default, neglect or misconduct absent
willful misconduct, bad faith or gross negligence (each of which must be determined by a final,
non-appealable judgment of a court of competent jurisdiction).

Section 3.3 Resignation And Removal; Appointment of Successor.

     (a) The Rights Agent may resign from its duties at any time by giving written notice thereof
to Parent specifying a date when such resignation shall take effect, which notice shall be sent at
least thirty (30) days prior to the date so specified.

     (b) If at any time the Rights Agent shall become incapable of acting, any Holder of a CVR may,
on behalf of himself and all others similarly situated, petition any court of competent

9

 

jurisdiction for the removal of the Rights Agent and the appointment of a successor Rights
Agent.

     (c) If the Rights Agent shall resign, be removed or become incapable of acting, Parent, by a
Board Resolution, shall promptly appoint a qualified successor Rights Agent who may (but need not)
be a Holder but shall not be an officer of Parent. The successor Rights Agent so appointed shall,
forthwith upon its acceptance of such appointment in accordance with this Section 3.3(c),
become the successor Rights Agent. The retiring Rights Agent shall deliver all relevant books and
records to the successor Rights Agent.

     (d) Parent shall give notice of each resignation and each removal of a Rights Agent and each
appointment of a successor Rights Agent by mailing written notice of such event by first-class
mail, postage prepaid, to the Holders as their names and addresses appear in the CVR Register.
Each notice shall include the name and address of the successor Rights Agent. If Parent fails to
send such notice within ten days after acceptance of appointment by a successor Rights Agent, the
successor Rights Agent shall cause the notice to be mailed at the expense of Parent.

Section 3.4 Acceptance of Appointment By Successor.

     Every successor Rights Agent appointed hereunder shall execute, acknowledge and deliver to
Parent and to the retiring Rights Agent an instrument accepting such appointment and a counterpart
of this Agreement, and thereupon such successor Rights Agent, without any further act, deed or
conveyance, shall become vested with all the rights, powers, trusts and duties of the retiring
Rights Agent; but, on request of Parent or the successor Rights Agent, such retiring
Rights Agent shall execute and deliver an instrument transferring to such successor Rights Agent
all the rights, powers and trusts of the retiring Rights Agent.

ARTICLE IV

OTHER COVENANTS

Section 4.1 List of Holders.

     Parent shall furnish or cause to be furnished to the Rights Agent in such form as
Rights Agent may reasonably require, the names and addresses of the Holders within five (5)
Business Days after the Effective Time.

Section 4.2 Information Requests.

     After receipt by the Holders of a CVR Payment Certificate or a Non-Achievement Certificate,
Parent shall promptly furnish (and in no event later than five (5) Business Days after receipt of a
request) to the Rights Agent all information and documentation in connection with this Agreement
and the CVRs that the Rights Agent or the 20% Holders may reasonably request in connection with the
determination of whether a Milestone Achievement Event or CVR Payment Event has occurred; provided,
however, that the Holders, in the aggregate, shall only be entitled to one (1) such request per
Milestone Achievement Event; provided, further, that such Holders shall be entitled to make an
additional request to address any questions directly relating

10

 

to Parent’s response to a previous request. The Rights Agent shall forward any information
and documentation it receives to the Holders who request such information within five (5) Business
Days of receipt.

Section 4.3 Annual Reporting.

     (a) If a Milestone Achievement Event has not occurred on or prior to each anniversary date of
the Effective Time during the CVR Achievement Period, then, within five (5) Business Days after
such date, Parent shall deliver to the Rights Agent an Officer’s Certificate stating that a
Milestone Achievement Event did not occur during such period (the “Non-Achievement
Certificate”). The Rights Agent shall promptly (and in no event later than five (5) Business
Days after receipt thereof) send each Holder a copy of such Non-Achievement Certificate at the
address as reflected in the CVR Register as of the date the Rights Agent received such
Non-Achievement Certificate.

     (b) Upon demand by the 20% Holders received by the Rights Agent within forty-five (45)
calendar days after distribution by the Rights Agent of a Non-Achievement Certificate (the
“Objection Period”), the Rights Agent shall deliver a written notice to the Parent, which
shall be prepared by such Holder or Holders (the “Written Notice”), (i) specifying that
such Holder or Holders object to the determination of Parent that a Milestone Achievement Event did
not occur and (ii) stating the reason upon which such Holder or Holders have determined that a
Milestone Achievement Event has occurred on or prior to the CVR Achievement Period (a “Notice
of Objection”). Notwithstanding anything to the contrary herein, the Rights Agent shall have
no duty or obligation to accept or deliver any Written Notice unless the Holders have provided such
evidence of their 20% ownership in the aggregate of the outstanding CVRs as the Rights Agent shall
reasonably request. Any dispute between the Parent and the 20% Holders arising from a Notice of
Objection shall be resolved in accordance with the procedure set forth in Section 7.10,
which decision shall be binding on the parties hereto and the Holders (including the Holders not
participating therein).

Section 4.4 Commercially Reasonable Efforts.

     Unless this Agreement and the CVRs shall have been terminated as provided herein, from and
after the date hereof, Parent shall use commercially reasonable efforts consistent with
pharmaceutical industry practice relating to products in a similar stage of marketing, development
and approval and with similar economic potential, and considering the regulatory, legal, business,
commercial and other facts and circumstances presented to Parent from and after the date hereof, to
(i) achieve, as soon as practicable, all Milestone Achievement Events, (ii) cause thereafter the
payment of the related Milestone Payments and (iii) disburse the corresponding Applicable Payments.

Section 4.5 Ability To Make Prompt Payment.

     Neither Parent nor any of its Subsidiaries shall enter into any agreement that would restrict
Parent’s right to be able to promptly disburse the Applicable Payments under this Agreement or
otherwise restrict Parent’s ability to fund such payments.

11

 

ARTICLE V

AMENDMENTS

Section 5.1 Amendments Without Consent of Holders.

     (a) Without the consent of any Holders, Parent, when authorized by a Board Resolution, and the
Rights Agent, at any time and from time to time, may enter into one or more amendments hereto, for
any of the following purposes:

          (i) subject to Section 6.1, to evidence the succession of another Person to Parent and
the assumption by any such successor of the covenants of Parent herein; or

          (ii) to evidence the termination of the CVR Registrar and the succession of another Person as
a successor CVR Registrar and the assumption by any successor of the obligations of the CVR
Registrar herein; provided that such succession and assumption is in accordance with the terms of
this Agreement.

     (b) Without the consent of any Holders, Parent, when authorized by a Board Resolution, and the
Rights Agent, in the Rights Agent’s sole and absolute discretion, at any time and from time to
time, may enter into one or more amendments hereto, for any of the following purposes:

          (i) to evidence the succession of another Person as a successor Rights Agent and the
assumption by any successor of the covenants and obligations of the Rights Agent herein, provided
that such succession and assumption is in accordance with the terms of this Agreement;

          (ii) to add to the covenants of Parent such further covenants, restrictions, conditions or
provisions as the Board of Directors and the Rights Agent shall consider to be for the protection
of the Holders; provided, that in each case, such provisions shall not adversely affect the
interests of the Holders;

          (iii) to cure any ambiguity, to correct or supplement any provision herein that may be
defective or inconsistent with any other provision herein, or to make any other provisions with
respect to matters or questions arising under this Agreement; provided, that in each case, such
provisions shall not adversely affect the interests of the Holders;

          (iv) as may be necessary or appropriate to ensure that the CVRs are not subject to
registration under the Securities Act or the Exchange Act; provided that such provisions shall not
adversely affect the interests of the Holders; or

          (v) any other amendments hereto for the purpose of adding, eliminating or changing any
provisions of this Agreement unless such addition, elimination or change is adverse to the
interests of the Holders.

     (c) Promptly after the execution by Parent and the Rights Agent of any amendment pursuant to
the provisions of this Section 5.1, Parent shall mail a notice thereof by first class mail

12

 

to the Holders at their addresses as they shall appear on the CVR Register, setting forth in
general terms the substance of such amendment.

Section 5.2 Amendments With Consent of Holders.

     (a) Subject to Section 5.1 (which amendments pursuant to Section 5.1 may be
made without the consent of the Holders), with the consent of the Holders of not less than a
majority of the outstanding CVRs, whether evidenced in writing or taken at a meeting of the
Holders, Parent, when authorized by a Board Resolution, and the Rights Agent may enter into one or
more amendments hereto for the purpose of adding, eliminating or changing any provisions of this
Agreement.

     (b) Promptly after the execution by Parent and the Rights Agent of any amendment pursuant to
the provisions of this Section 5.2, Parent shall mail a notice thereof by first class mail
to the Holders at their addresses as they shall appear on the CVR Register, setting forth in
general terms the substance of such amendment.

Section 5.3 Execution of Amendments.

     Prior to executing any amendment permitted by this Article V, the Rights Agent shall be
entitled to receive, and shall be fully protected in relying upon, an Officer’s Certificate and an
opinion of counsel stating that the execution of such amendment is authorized or permitted by this
Agreement. Notwithstanding anything herein to the contrary, the Rights Agent may, but is not
obligated to, enter into any such amendment that affects the Rights Agent’s own rights, privileges,
covenants, obligations, immunities or duties under this Agreement or otherwise.

Section 5.4 Effect of Amendments.

     Upon the execution of any amendment under this Article V, this Agreement shall be modified in
accordance therewith, such amendment shall form a part of this Agreement for all purposes and every
Holder shall be bound thereby.

ARTICLE VI

CONSOLIDATION, MERGER, SALE OR CONVEYANCE

Section 6.1 Parent May Not Consolidate, Etc.

     (a) Parent shall not consolidate with or merge into any other Person or convey, transfer or
lease its properties and assets substantially as an entirety to any Person, unless:

          (i) the Person formed by such consolidation or into which Parent is merged or the Person that
acquires by conveyance or transfer, or that leases, the properties and assets of Parent
substantially as an entirety (the “Surviving Person”) shall expressly assume payment of
amounts on all the CVRs and the performance of every duty and covenant of this Agreement on the
part of Parent to be performed or observed; and

13

 

          (ii) Parent has delivered to the Rights Agent an Officer’s Certificate, stating that such
consolidation, merger, conveyance, transfer or lease complies with this Article VI and that all
conditions precedent herein have been satisfied.

     (b) For purposes of this Section 6.1, “convey, transfer or lease its properties and
assets substantially as an entirety” shall mean (i) properties and assets contributing in the
aggregate at least sixty-five percent (65%) of Parent’s total consolidated revenues as reported in
Parent’s last available periodic financial report (quarterly or annual, as the case may be) or (ii)
properties or assets compromising a all or substantially all of the Company’s product candidates
related to the Milestone Events, namely SBR-087 and TRU-016.

Section 6.2 Successor Substituted.

     Upon any consolidation of or merger by Parent with or into any other Person, or any
conveyance, transfer or lease of the properties and assets substantially as an entirety to any
Person in accordance with Section 6.1, the Surviving Person shall succeed to, and be
substituted for, and may exercise every right and power of, Parent under this Agreement with the
same effect as if the Surviving Person had been named as Parent herein, and thereafter, except in
the case of a lease, the predecessor Person shall be relieved of all obligations and covenants
under this Agreement and the CVRs.

ARTICLE VII

GENERAL PROVISIONS

Section 7.1 Notices To Rights Agent And Parent.

     All notices, requests, claims, demands and other communications under this Agreement shall be
in writing and shall be deemed given (and duly received): (a) at the time of personal delivery; (b)
one (1) Business Day after sent by fax (providing proof of transmission and confirmation of
transmission by telephonic notice to the applicable contact person) to the fax numbers below (or to
such other fax number for a party as shall be specified by like notice); or (c) one (1) Business
Day after deposit with an overnight courier (providing proof of delivery and confirmation of
receipt by telephonic notice to the applicable contact person) to the parties at the following
addresses (or at such other address for a party as shall be specified by like notice):

if to the Rights Agent, to

Mellon Investor Services LLC

520 Pike Street, Suite 1220

Seattle, WA 98101

Attn: Thomas L. Cooper

Facsimile: 206-674-3059

14

 

with a copy to:

Mellon Investor Services LLC

Newport Office Center VII,

480 Washington Blvd.,

Jersey City, NJ 07310

Attention: General Counsel

if to the Parent, to

Emergent BioSolutions Inc.

2273 Research Boulevard, Suite 400

Rockville, MD 20850

Attn: General Counsel

Facsimile: 301-795-1899

with a copy to:

Bingham McCutchen LLP

2020 K Street NW

Washington, D.C., 20006

Attention: Carl A. Valenstein

Facsimile: 202-373-6448

Section 7.2 Notice To Holders.

     Where this Agreement provides for notice to Holders, such notice shall be deemed given four
(4) Business Days after deposit in the United States mail by first class mail, to each Holder
affected by such event, at his, her or its address as it appears in the CVR Register. In any case
where notice to Holders is given by mail, neither the failure to mail such notice, nor any defect
in any notice so mailed, to any particular Holder shall affect the sufficiency of such notice with
respect to other Holders.

Section 7.3 Interpretations.

     When a reference is made in this Agreement to an Article or a Section, such reference shall be
to an Article or a Section of this Agreement unless otherwise indicated. The headings are for
reference purposes only and shall not affect in any way the meaning or interpretation of this
Agreement. Whenever the word “include,” “includes” or “including” is used in this Agreement, it
shall be deemed to be followed by the words “without limitation.” The words “hereof,” “herein” and
“hereby” refer to this Agreement

Section 7.4 Successors and Assigns.

     Neither this Agreement nor any of the rights, interests or obligations under this Agreement
shall be assigned or delegated, in whole or in part, by operation of Law or otherwise

15

 

by any of the parties without the prior written consent of the other parties. All covenants
and agreements in this Agreement by Parent shall bind its successors and assigns, whether so
expressed or not.

Section 7.5 Governing Law.

     THIS AGREEMENT AND THE CVRS SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS
OF THE STATE OF DELAWARE, WITHOUT REGARD TO THE CONFLICTS OF LAWS PRINCIPLES THEREOF THAT WOULD
CAUSE THE APPLICATION OF LAWS OF ANY JURISDICTION OTHER THAN THOSE OF THE STATE OF DELAWARE;
PROVIDED, HOWEVER, THAT ALL PROVISIONS REGARDING THE RIGHTS, DUTIES, RESPONSIBILITIES AND
OBLIGATIONS OF THE RIGHTS AGENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF
THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE.

Section 7.6 Severability Clause.

     In case any one or more of the provisions contained in this Agreement shall for any reason be
held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or
unenforceability shall not affect any other provisions of this Agreement, but this Agreement shall
be construed as if such invalid or illegal or unenforceable provision had never been contained
herein; provided, however, that if such modified provision shall affect the rights, immunities,
duties or obligations or the Rights Agent, the Rights Agent shall be entitled to resign
immediately. Upon such determination that any term or other provision is invalid, illegal or
unenforceable, the court or other tribunal making such determination is authorized and instructed
to modify this Agreement so as to effect the original intent of the parties as closely as possible
so that the transactions and agreements contemplated herein are consummated as originally
contemplated to the fullest extent possible.

Section 7.7 Counterparts.

     This Agreement may be executed in one or more counterparts, all of which shall be considered
one and the same agreement and shall become effective when one or more counterparts have been
signed by each of the parties and delivered to the other parties. Any facsimile copy or electronic
mail copy message in “pdf” or similar format of an executed counterpart of this Agreement will be
deemed to be an executed original thereof.

Section 7.8 Termination.

     This Agreement shall be terminated and of no force or effect, and the parties hereto shall
have no liability hereunder, upon the expiration of the CVR Achievement Period; provided however
that the parties’ rights and obligations hereunder with respect to any Milestone Achievement Event
or any dispute related thereto (including, without limitation, the resolution of any Notice of
Objection) that occurs during the CVR Achievement Period shall continue until such time as is
necessary to deliver any CVR Payment Amount payable in connection with, or to resolve a dispute
related to, such Milestone Achievement Event under the terms of this Agreement.

16

 

Section 7.9 Entire Agreement; No Third-Party Beneficiaries.

     As it relates to the Rights Agent, this Agreement represents the entire understanding of the
parties hereto with reference to the subject matter of this Agreement and this Agreement supersedes
any and all other oral or written agreements made with respect to the subject matter of this
Agreement. As it relates to all other parties hereto, this Agreement (including the documents and
instruments referred to herein and the Annexes and Schedules attached hereto) and the Merger
Agreement constitutes the entire agreement, and supersedes all prior agreements and understandings,
both written and oral, among the parties, or any of them, with respect to the subject matter of
this Agreement. If and to the extent that any provision of this Agreement is inconsistent or
conflicts with the Merger Agreement, this Agreement shall govern and be controlling. Nothing in
this Agreement, express or implied, shall give to any Person (other than the parties hereto, the
Holders and their permitted successors and assigns hereunder) any benefit or any legal or equitable
right, remedy or claim under this Agreement or under any covenant or provision herein contained,
all such covenants and provisions being for the sole benefit of the parties hereto, the Holders and
their permitted successors and assigns.

Section 7.10 Negotiation; Consent to Jurisdiction; Venue; Waiver of Trial by Jury.

     (a) Parent and the 20% Holders shall negotiate in good faith for a period of thirty (30) days
to resolve any controversy or claim arising out of or relating to this Agreement, or the breach
thereof.

     (b) After expiration of the thirty (30) day period contemplated by Section 7.10(a), if
the underlying controversy or claim has not been resolved, then, the Parent or the 20% Holders
(each a “Litigation Party”) may commence litigation, but only in a federal or state court
of competent jurisdiction in Delaware. No Holder shall commence any litigation to resolve any
controversy or claim arising out of or relating to this Agreement, or breach thereof, unless
approved by the 20% Holders. The losing Litigation Party in such litigation will pay all the
prevailing Litigation Party’s attorneys’ fees, court costs, and other expenses related to that
litigation, and in the event of a dispute brought by or on behalf of the 20% Holders in which
Parent is the prevailing Litigation Party, Parent shall be entitled to offset such amounts owed to
Parent against the Applicable Payments, if any.

     (c) Each of the Litigation Parties irrevocably submits to the exclusive jurisdiction of the
state courts of Delaware and to the jurisdiction of the United States District Court for the
District of Delaware for the purpose of any Action arising out of or relating to this Agreement,
and each of the Litigation Parties irrevocably agrees that all claims in respect to such Action may
be heard and determined exclusively in any Delaware state or federal court sitting in the State of
Delaware. Each of the Litigation Parties agrees that a final judgment in any Action shall be
conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other
manner provided by Law.

     (d) Each of the Litigation Parties irrevocably consents to the service of any summons and
complaint and any other process in any other action relating to this Agreement, on behalf of itself
or its property, by the personal delivery of copies of such process to such Litigation Party.

17

 

Nothing in this Section 7.10(d) shall affect the right of any Litigation Party to
serve legal process in any other manner permitted by Law.

     (e) EACH LITIGATION PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY THAT MAY ARISE UNDER
THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH
LITIGATION PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH LITIGATION PARTY MAY
HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR
RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH LITIGATION
PARTY CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER
LITIGATION PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER LITIGATION PARTY WOULD
NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (B) EACH SUCH LITIGATION
PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) EACH SUCH LITIGATION
PARTY MAKES THIS WAIVER VOLUNTARILY AND (D) EACH SUCH LITIGATION PARTY HAS BEEN INDUCED TO ENTER
INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE WAIVERS AND CERTIFICATIONS IN THIS SECTION
7.10(E).

     (f) Consent to Representation by Fenwick & West LLP. In the event of any dispute
following the Effective Time between Parent, on the one hand, and the Holders, on the other hand,
Parent hereby consents to the representation by Fenwick & West LLP of any of the Holders
notwithstanding the prior representation of the Company by Fenwick & West LLP.

ARTICLE VIII

MISCELLANEOUS

Section 8.1 USA Patriot Act

     Parent acknowledges that the Rights Agent is subject to the customer identification program
(“Customer Identification Program”) requirements under the USA PATRIOT Act and its
implementing regulations, and that the Rights Agent must obtain, verify and record information that
allows the Rights Agent to identify the Parent. Accordingly, prior to accepting an appointment
hereunder, the Rights Agent may request information from the Parent that will help the Rights Agent
to identify the Parent, including without limitation the Parent’s physical address, tax
identification number, organizational documents, certificate of good standing, license to do
business, or any other information that the Parent deems necessary. The Parent agrees that the
Rights Agent cannot accept an appointment hereunder unless and until the Rights Agent verifies the
Parent’s identity in accordance with the Customer Identification Program requirements.

Section 8.2 Incentive Compensation Program

     The Bank of New York Mellon Corporation (“BNYM”) has adopted an incentive compensation
program designed (i) to facilitate clients gaining access to and being provided with

18

 

explanations about the full range of products and services offered by BNYM and its
subsidiaries and (ii) to expand and develop client relationships. This program may lead to the
payment of referral fees and/or bonuses to employees of BNYM or its subsidiaries who may have been
involved in a referral that resulted in the execution of this Agreement, obtaining of products or
services covered by this Agreement or which may be ancillary or supplemental to such products or
services. And such referral fees or bonuses are funded solely out of fees and commissions paid
under this Agreement or with respect to such ancillary or supplemental products or services.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

19

 

     IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed on its behalf
by its duly authorized officers as of the day and year first above written.

	 	 	 	 	 
	 	EMERGENT BIOSOLUTIONS INC.

 	 
	 	By:  	/s/ Fuad El-Hibri	 
	 	 	Name:  	Fuad El-Hibri	 
	 	 	Title:  	Chairman & CEO	 
	 
	 	TRUBION PHARMACEUTICALS, INC.

 	 
	 	By:  	/s/  Steven Gillis	 
	 	 	Name:  	Steven Gillis, Ph.D. 	 
	 	 	Title:  	Executive Chairman and Acting President 	 
	 
	 	

MELLON INVESTOR SERVICES LLC

 	 
	 	By:  	/s/  Thomas L. Cooper	 
	 	 	Name:  	Thomas L. Cooper 	 
	 	 	Title:  	Vice President 	 

 

 

	 	 	 	 	 

Annex A

	 	 	 	 	 
	CVR PAYMENT EVENT	 	APPLICABLE PAYMENT	 
	Milestone Events under the Wyeth Agreement
	 	 	 	 
	Initiation of dosing in the first Phase III Clinical
Study for the first Major Indication (CD 20 Products)
	 	$	6,250,000	 
	Initiation of dosing in the first Phase III Clinical
Study for the second Major Indication (CD 20 Products)
	 	$	5,000,000	 
	Initiation of dosing in the first Phase II Clinical
Study for a product candidate directed towards a non-CD
20 target)
	 	$	750,000	 
	Pfizer/Wyeth subtotal
	 	$	12,000,000	 
	 
	 	 	 	 
	Milestone Events under the Facet Agreement
	 	 	 	 
	Initiation of the first Phase II Clinical Study
(includes transition to Phase II portion of a Phase
I/II Clinical Study)
	 	$	1,747,904.38	 
	Initiation of the first Phase III Clinical Study in an
oncology indication (includes transition to the pivotal
phase of a Phase II/III Clinical Study)
	 	$	15,000,000	 
	Achievement Event under the Facet Agreement
	 	 	 	 
	Release TRU-016*
	 	$	10,000,000	 
	Abbott / Facet subtotal
	 	$	26,747,904.38	 

 

			
	*	 	Release of TRU-016 manufactured pursuant to the Facet Agreement for use in clinical studies, with
such milestone to be paid no earlier than November 30, 2011 provided TRU -016 remains under
Co-Development at November 30, 2011 (other than because of Company’s successor or assignee
exercised or was deemed to have exercised its Opt-Out Option). In the event that either the Joint
Development or Joint Steering Committee governing the TRU-016 collaboration elect to delay product
manufacture, or in the event such manufacture is delayed for any reason, so long as TRU-016 remains
under Co-Development on November 30, 2011 (other than because of Company’s successor or assignee
exercised or was deemed to have exercised its Opt-Out Option) such milestone payment shall be paid
on December 1, 2011.

 

 

Schedule 1

BNY MELLON SHAREOWNER SERVICES 

Schedule of Fees

As CVR Rights Agent

	 	 	 	 	 

	Annual Administration Fee
	 	$	5,000.00	 
	• Up to 1,000 CVR Holder Accounts
	 	 	 	 
	• No Dividend Distributions
	 	 	 	 
	• Review of Emergent’s Authorization, per transfer
	 	 	 	 
	 
	 	 	 	 
	Receipt & Set-Up of Distribution File, per file
	 	$	1,500.00	 
	 
	 	 	 	 
	Additional Services, if applicable
	 	 	 	 
	• Exercising of Rights
	 	By Appraisal
	• Rights Redemption Payment
	 	By Appraisal
	• Legal Out-of-Pocket Expense
	 	 	 	 
	• Agreement Review
	 	$	2,000.00	 
	• Amendment Review
	 	$	900.00exv10w2

Exhibit 10.2

SUPPORT AGREEMENT

     This SUPPORT AGREEMENT (this “Agreement”), is dated as of August 12, 2010, by and
between Emergent BioSolutions Inc., a Delaware corporation (“Parent”), and the undersigned
stockholder (“Stockholder”) of Trubion Pharmaceuticals, Inc., a Delaware corporation (the
“Company”).

W I T N E S S E T H:

     WHEREAS, Parent, 35406 LLC, a Delaware limited liability company and wholly owned direct
subsidiary of Parent (the “LLC”), 30333 Inc., a Delaware corporation and wholly owned
indirect subsidiary of Parent (“Merger Sub”), and the Company, have entered into an
Agreement and Plan of Merger dated as of August 12, 2010 (the “Merger Agreement”), pursuant
to which the Merger Sub will merge (the “Merger”) with and into the Company, with the
Company surviving the Merger as an indirect subsidiary of Parent, and then merging with and into
the LLC with the LLC being the surviving entity of the LLC Merger;

     WHEREAS, as a condition to Parent’s willingness to enter into and perform its obligations
under the Merger Agreement, Parent has required that Stockholder agree, and Stockholder desires to
agree (i) to vote, or cause to be voted, in person or by proxy all of the shares owned by
Stockholder and subject to this Agreement as set forth in Column C of Annex A (the “Subject
Shares”), in favor of (a) approval of the Merger and the other transactions contemplated by the
Merger Agreement and the other agreements related thereto (the “Related Agreements”), and
(b) any other matter that is required by applicable law or by any Governmental Entity to be
approved by stockholders of the Company to consummate the Merger and the other transactions
contemplated by the Merger Agreement and the Related Agreements, and against any Competing
Transaction; (ii) to grant Parent a proxy to vote the Subject Shares on behalf and in the name of
Stockholder; and (iii) to take the other actions, or to refrain from taking certain enumerated
actions, each as further described herein;

     WHEREAS, Stockholder desires to express his support for the Merger and the other transactions
contemplated by the Merger Agreement and the Related Agreements; and

     WHERAS, Capitalized terms used herein and not otherwise defined herein shall have the meanings
ascribed to such terms in the Merger Agreement.

     NOW, THEREFORE, in consideration of the foregoing premises and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto
hereby agree as follows:

     1. Agreement to Vote; Non-Solicit; Irrevocable Proxy.

     1.1. Agreement to Vote. Subject to Section 1.4 below, Stockholder hereby agrees that,
during the time this Agreement is in effect, at any meeting of the stockholders of the Company
(including, but not limited to, the special meeting of the Company’s stockholders to consider and
vote upon the adoption and approval of the Merger Agreement and the Related Agreements and the
transactions contemplated thereby (the “Special Meeting”)), however called, or any
adjournment or postponement thereof, and in response to any request for any written

 

 

consent of the stockholders of the Company, Stockholder shall be present (in person or by
proxy) and vote (or cause to be voted) all of the Subject Shares (a) in favor of (i) approval of
the Merger and the other transactions contemplated by the Merger Agreement and the Related
Agreements, and approval of any other matter that is required by applicable law or by any
Governmental Entity to be approved by the stockholders of the Company to consummate the Merger and
the other transactions contemplated by the Merger Agreement and the Related Agreements; and (b)
against (i) any other Competing Transaction, and (ii) any other action that could reasonably be
expected to (A) impede, interfere with, delay, postpone or attempt to discourage or have the effect
of discouraging the consummation of the Merger and the other transactions contemplated by the
Merger Agreement and the Related Agreements, (B) constitute or result in a breach of any of the
representations, warranties covenants, or other obligations or agreements of the Company under the
Merger Agreement that would reasonably be expected to have a material adverse effect on the Company
or (C) impair or adversely affect the ability of the Company to consummate the Merger and the other
transactions contemplated by the Merger Agreement and the Related Agreements.

     1.2. Non-Solicit. Stockholder hereby agrees that, during the time this Agreement is
in effect neither Stockholder nor any of Stockholder’s controlled affiliates or representatives
(other than any such affiliate or representative who is a director of the Company) shall (a)
solicit, initiate or intentionally encourage (including by way of providing information) the
submission of any Competing Transaction or (ii) participate in any discussions or negotiations
regarding, or take any other action to knowingly facilitate, induce or encourage the making of any
proposal that constitutes, or may reasonably be expected to lead to, any Competing Transaction, (b)
approve or recommend, or publicly propose to resolve to approve or recommend, a Competing
Transaction, (c) enter into any merger agreement, letter of intent, agreement in principle, share
purchase agreement, asset purchase agreement or share exchange agreement, option agreement or other
similar agreement relating to a Competing Transaction, (d) enter into any agreement requiring the
Stockholder to abandon, terminate or fail to consummate the Merger and the other transactions
contemplated by the Merger Agreement and the Related Agreements or (e) propose or agree to do any
of the foregoing.

     1.3. Irrevocable Proxy. Solely with respect to the matters described in Section 1.1,
and subject to Section 1.4 below, if Stockholder has not taken a Qualifying Action (as defined
below) on or prior to the fifth (5th) Business Day prior to the Special Meeting (including any
adjournments or postponements thereof) or any other meeting, date or event upon which stockholders
of the Company will be asked to vote with respect to the matters described in Section 1.1 (such
meeting, date or event, the “Voting Event”), Stockholder hereby irrevocably (to the fullest
extent permitted by law and subject to the termination of this Agreement as set forth in Section
1.4) appoints Parent as its proxy with full power of substitution (which proxy is irrevocable and
which appointment is coupled with an interest, including for purposes of all applicable provisions
of the Delaware General Corporation Law) to vote in its discretion all Subject Shares owned by
Stockholder beneficially and of record solely on the matters described in Section 1.1 effective
from and after the third (3rd) Business Day prior to the Voting Event and until the date of the
applicable Voting Event. Stockholder agrees to execute any further agreement or form reasonably
necessary or appropriate to confirm and effectuate the grant of the proxy contained herein.
“Qualifying Action” means either (a) the delivery by Stockholder or the Company to Parent
of a copy of such Stockholder’s duly executed and valid proxy (and any

2

 

amendment of such proxy) with respect to the Special Meeting or other Voting Event, provided
the votes reflected in such proxy or amendment thereof are consistent with Stockholder’s voting
obligations under this Agreement with respect to the matter(s) in question or (b) the delivery by
Stockholder to Parent of a written certificate signed by Stockholder certifying that Stockholder
shall attend the Special Meeting or other Voting Event in person (if a meeting of stockholders) and
vote the Subject Shares in accordance with Section 1.1 hereof, provided that in the event
that a Qualifying Action is subsequently rescinded, revoked or modified in any manner inconsistent
with the requirements of Section 1.1, or if Stockholder does not attend and vote as required
hereunder at any Voting Event, Stockholder shall be deemed to have affirmed as of the time of the
Voting Event the proxy with respect to the Subject Shares granted in this Section (notwithstanding
any other action taken since the date hereof) and Parent (or its designee) shall be entitled to the
proxy and vote the Subject Shares in its discretion at or in connection with the applicable Voting
Event.

     1.4. Termination of Obligations and Covenants of Stockholder and Proxy. The
obligations and covenants of the Stockholder pursuant to this agreement and the proxy granted to
Parent herein with respect to the Subject Shares automatically shall terminate and be of no further
force or effect from and after any termination of the Merger Agreement pursuant to the terms
thereof.

     2. Representations and Warranties of Stockholders. Stockholder hereby represents and
warrants to Parent as follows:

     2.1. Power; Due Authorization; Binding Agreement. Stockholder has full power and
authority to execute and deliver this Agreement, to perform his obligations hereunder and to
consummate the transactions contemplated hereby. This Agreement has been duly and validly executed
and delivered by Stockholder and constitutes a valid and binding agreement of Stockholder,
enforceable against Stockholder in accordance with its terms, except that enforceability may be
subject to the effect of any applicable bankruptcy, reorganization, insolvency, moratorium or other
similar laws affecting or relating to the enforcement of creditors rights generally and to general
principles of equity.

     2.2. Ownership of Shares. All Subject Shares (a) are, and will be as of the date of
the Stockholders Meeting or any other applicable Voting Event, held free and clear of all liens and
encumbrances, and (b) will not be subject to any proxies (other than pursuant to this Agreement) as
of the date of the Special Meeting or any other applicable Voting Event. As of the date hereof,
Stockholder has, and as of the date of the Special Meeting or other Voting Event will have (except
as otherwise permitted or required by this Agreement), sole voting power and sole dispositive power
with respect to all of the Subject Shares.

     2.3. No Conflicts. The execution and delivery of this Agreement by Stockholder does
not, and the performance of the terms of this Agreement by Stockholder will not, (a) require
Stockholder to obtain the consent or approval of, or make any filing with or notification to, any
Governmental Entity, (b) require the consent or approval of any other Person pursuant to any
agreement, obligation or instrument binding on Stockholder or his properties and assets, (c)
conflict with or violate any organizational document or any law applicable to Stockholder or
pursuant to which any of his properties or assets are bound or (d) violate any other agreement to

3

 

which Stockholder or any of his affiliates is a party including any voting agreement,
stockholders agreement, irrevocable proxy or voting trust, except for any consent, approval, filing
or notification which has been obtained as of the date hereof or the failure of which to obtain,
make or give would not, or any conflict or violation which would not, impair in any material
respect Stockholder’s ability to perform his obligations under this Agreement or in any event
impair Stockholder’s ability to perform his obligations under Section 1.1 hereof. Except for this
Agreement, the Subject Shares are not, with respect to the voting or transfer thereof, subject to
any other agreement or third party rights, including any voting agreement, stockholders agreement,
irrevocable proxy or voting trust.

     2.4. Acknowledgment. Stockholder understands and acknowledges that Parent entered
into the Merger Agreement in reliance upon such Stockholder’s execution, delivery and performance
of this Agreement.

     3. Certain Covenants of Stockholder. Stockholder hereby covenants and agrees with
Parent as follows:

     3.1. Restriction on Transfer, Proxies and Non-Interference. Stockholder hereby
agrees, while this Agreement is in effect, not to (a) sell, transfer, pledge, encumber, assign or
otherwise dispose of, or enter into any contract, option or other arrangement or understanding
other than this Agreement with respect to the sale, transfer, pledge, encumbrance, assignment or
other disposition of, or limitation on the voting rights of, any of the Subject Shares, (b) grant
any proxies or powers of attorney, deposit any Subject Shares into a voting trust or enter into a
voting agreement with respect to any Subject Shares (or attempt or purport to revoke or supersede
the proxy granted to Parent hereunder), (c) take any action that reasonably could cause any
representation or warranty of Stockholder contained herein to become untrue or incorrect or have
the effect of preventing or disabling Stockholder from performing Stockholder’s covenants or other
obligations under this Agreement or (d) commit or agree to take any of the foregoing actions. Any
transfer of any Subject Shares in violation of this provision shall be null and void. If any
involuntary transfer of any of the Subject Shares shall occur (including a sale by Stockholder’s
trustee in any bankruptcy, or a sale to a purchaser at any creditor’s or court sale), the
transferee (which term, as used herein, shall include any and all transferees and subsequent
transferees of the initial transferee) shall take and hold such Subject Shares subject to all of
the restrictions, liabilities and rights under this Agreement, which shall continue in full force
and effect until the earlier of (i) the date on which such restrictions, liabilities and rights
terminate pursuant to this Agreement and (ii) a valid termination of this Agreement.

     3.2. No Limitations on Actions. Stockholder signs this Agreement solely in his
capacity as the record and/or beneficial owner, as applicable, of the Subject Shares; nothing
herein shall limit or affect the Company’s rights available at law or in equity in connection with
the Merger Agreement.

     3.3. Further Assurances. From time to time, at the request of Parent and without
further consideration, Stockholder shall execute and deliver such additional documents and
instruments and take all such further action as may be reasonably requested by Parent to effectuate
or evidence the purpose and intent of this Agreement.

4

 

     4. Miscellaneous.

     4.1. Entire Agreement; Assignment. This Agreement constitutes the entire agreement
among the parties with respect to the subject matter hereof and supersedes all other prior
agreements and understandings, both written and oral, among the parties with respect to the subject
matter hereof. Nothing in this Agreement, express or implied, is intended to or shall confer upon
any other Person any right, benefit or remedy of any nature whatsoever under or by reason of this
Agreement. This Agreement shall not be assigned by operation of law or otherwise and shall be
binding upon and inure solely to the benefit of each party hereto.

     4.2. Amendments. This Agreement may not be modified, amended, altered or
supplemented, except upon the execution and delivery of a written agreement executed by each of the
parties hereto.

     4.3. Notices. All notices, requests, claims, demands and other communications
hereunder shall be in writing and shall be given (and shall be deemed to have been duly received if
so given) by hand delivery, by facsimile transmission or by any courier service, such as Federal
Express, providing proof of delivery. All communications hereunder shall be delivered to the
respective parties at the following addresses:

If to Stockholder to:

See Annex A

with a copy (which shall not constitute notice) to:

Fenwick & West LLP (Seattle)

1191 Second Avenue, 10th Floor

Seattle, WA 98101

Attention: Alan C. Smith, Esq.

Facsimile: 206.389.4511

If to Parent to:

Emergent BioSolutions Inc.

2273 Research Boulevard, Suite 400

Rockville, MD 20850

Attention: General Counsel

Facsimile: 301.795.1899

with a copy (which shall not constitute notice) to:

Bingham McCutchen LLP

2020 K Street, NW

Washington, DC 20006

Attention: Carl A. Valenstein, Esq.

Facsimile: 202.373.6448

5

 

or to such other address as the person to whom notice is given may have previously furnished to the
others in writing in the manner set forth above.

     4.4. Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE
WITH, THE LAWS OF THE STATE OF DELAWARE, WITHOUT REGARD TO THE CONFLICTS OF LAWS PRINCIPLES THEREOF
THAT WOULD CAUSE THE APPLICATION OF LAWS OF ANY JURISDICTION OTHER THAN THOSE OF THE STATE OF
DELAWARE.

     4.5. Consent to Jurisdiction; Venue. Each of the Litigation Parties irrevocably
submits to the exclusive jurisdiction of the state courts of Delaware and to the jurisdiction of
the United States District Court for the District of Delaware for the purpose of any Action arising
out of or relating to this Agreement, and each of the Litigation Parties irrevocably agrees that
all claims in respect to such Action may be heard and determined exclusively in any Delaware state
or federal court sitting in the State of Delaware. Each of the Litigation Parties agrees that a
final judgment in any Action shall be conclusive and may be enforced in other jurisdictions by suit
on the judgment or in any other manner provided by Law.

     4.6. Waiver of Trial by Jury. EACH LITIGATION PARTY ACKNOWLEDGES AND AGREES THAT ANY
CONTROVERSY THAT MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT
ISSUES, AND THEREFORE EACH SUCH LITIGATION PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY
RIGHT SUCH LITIGATION PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR
INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS
AGREEMENT. EACH LITIGATION PARTY CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE, AGENT OR
ATTORNEY OF ANY OTHER LITIGATION PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER
LITIGATION PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (B)
EACH SUCH LITIGATION PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) EACH
SUCH LITIGATION PARTY MAKES THIS WAIVER VOLUNTARILY AND (D) EACH SUCH LITIGATION PARTY HAS BEEN
INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE WAIVERS AND CERTIFICATIONS IN THIS
SECTION 4.6.

     4.7. Remedies. The parties agree that irreparable damage would occur in the event
that any provisions of this Agreement were not performed in accordance with their specific terms or
were otherwise breached. It is accordingly agreed that the parties hereto shall be entitled to an
injunction or injunctions to prevent breaches or threatened breaches of this Agreement and to
enforce specifically the terms and provisions of this Agreement, this being in addition to any
other remedy to which they may be entitled under any applicable law or in equity.

     4.8. Counterparts. This Agreement may be executed by facsimile or PDF signature and
in two (2) or more counterparts, each of which shall be deemed to be an original, but all of which
when taken together shall constitute one and the same Agreement.

6

 

     4.9. Severability. Whenever possible, each provision or portion of any provision of
this Agreement will be interpreted in such manner as to be effective and valid under applicable law
but if any provision or portion of any provision of this Agreement is held to be invalid, illegal
or unenforceable in any respect under any applicable law or rule in any jurisdiction, such
invalidity, illegality or unenforceability will not affect any other provision or portion of any
provision in such jurisdiction, and this Agreement will be reformed, construed and enforced in such
jurisdiction as if such invalid, illegal or unenforceable provision or portion of any provision had
never been contained herein.

     4.10. Interpretation. When a reference is made in this Agreement to a Section, such
reference shall be to a Section of this Agreement unless otherwise indicated. The headings
contained in this Agreement are for reference purposes only and shall not affect in any way the
meaning or interpretation of this Agreement. Whenever the words “include,” “includes,” or
“including” are used in this Agreement, they shall be deemed to be followed by the words “without
limitation.” Unless the context otherwise requires, words describing the singular number shall
include the plural and vice versa, words denoting any gender shall include all genders and words
denoting natural Persons shall include corporations, partnerships and other Persons and vice versa.

     4.9 Savings Clause. Notwithstanding anything to the contrary contained herein, in the
event that the number of Subject Shares, when aggregated with the number of shares subject to other
support agreements, by and between Parent and other holders of the voting stock of the Company
(collectively, the “Other Support Agreements”) would exceed 35% of the voting power of the
then-outstanding shares of capital stock of the Company, this Agreement shall be deemed to apply
only to the maximum number of shares subject hereto as would not result in the total shares with
voting power subject to this Agreement and the Other Support Agreements exceeding such 35% maximum
amount, with any resulting adjustment in the amount of shares subject to this Agreement and the
Other Support Agreements to be allocated pro rata among such agreements based on the relative
number of shares subject to such agreements.

[Signature Page Follows]

7

 

     IN WITNESS WHEREOF, the parties hereto have caused this Support Agreement to be duly
executed as of the date first above written.

	 	 	 	 	 	 	 	 	 	 
	“Parent”	 	 	 	“Stockholder”	 
	 
	 	 	 	 	 	 	 	 	 
	Emergent BioSolutions Inc.	 	 	 	ARCH Venture Fund V, L.P.	 
	 
	 	 	 	 	 	By:	 	ARCH Venture Partners V, L.P.	 
	 
	 	 	 	 	 	 	 	Its: General Partner	 
	 
	By:
	 	 	 	 	 	By:	 	ARCH Venture Partners V, L.L.C.	 
	 
	 
	 	 	 	 	 	 	 	 
	 
	 	Name:	 	 	 	 	 	Its: General Partner	 
	 
	 	Its:	 	 	 	 	 	 	 
	 
	 	 	 	 	 	By:	 	 	 
	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	Name:	 
	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	Its:                   Managing Director	 
	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	ARCH V Entrepreneurs Fund V, L.P.	 
	 
	 	 	 	 	 	By:	 	ARCH Venture Partners V, L.P.	 
	 
	 	 	 	 	 	 	 	Its: General Partner	 
	 
	 
	 	 	 	 	 	By:	 	ARCH Venture Partners V, L.L.C.	 
	 
	 	 	 	 	 	 	 	Its: General Partner	 
	 
	 
	 	 	 	 	 	By:	 	 	 
	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	Name:	 
	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	Its:                   Managing Director	 
	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	Healthcare Focus Fund, L.P.	 
	 
	 	 	 	 	 	By:	 	ARCH Venture Partners V, L.P.	 
	 
	 	 	 	 	 	 	 	Its: General Partner	 
	 
	 
	 	 	 	 	 	By:	 	ARCH Venture Partners V, L.L.C.	 
	 
	 	 	 	 	 	 	 	Its: General Partner	 
	 
	 
	 	 	 	 	 	By:	 	 	 
	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	Name:	 
	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	Its:                   Managing Director	 

 

 

     IN WITNESS WHEREOF, the parties hereto have caused this Support Agreement to be duly executed
as of the date first above written.

	 	 	 	 	 	 	 	 	 	 
	“Parent”	 	 	 	“Stockholder”	 
	 
	 	 	 	 	 	 	 	 	 
	Emergent BioSolutions Inc.	 	 	 	Frazier Affiliates IV, L.P.	 
	 
	 	 	 	 	 	By: 	 	FHM IV, LP	 
	 
	 	 	 	 	 	 	 	Its general partner	 
	By: 
	 	 	 	 	 	By: 	 	FHM IV, LLC	 
	 
	 	 	 	 	 	 	 	 
	 
	 	Name:	 	 	 	 	 	Its general partner	 
	 
	 	Its:	 	 	 	 	 	 	 
	 
	 		 	 	 	 	 	 	 
	 
	 	 	 	 	 	By: 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	Name: Tom Hodge	 
	 
	 	 	 	 	 	 	 	Its:	 
	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Frazier Healthcare III, L.P.	 
	 
	 	 	 	 	 	By: 	 	FHM III, LLC	 
	 
	 	 	 	 	 	 	 	Its                                         	 
	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	By: 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	Name: Tom Hodge	 
	 
	 	 	 	 	 	 	 	Its:	 
	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Frazier Affiliates III, L.P.	 
	 
	 	 	 	 	 	By: 	 	FHM III, LLC	 
	 
	 	 	 	 	 	 	 	Its                                         	 
	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	By: 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	Name: Tom Hodge	 
	 
	 	 	 	 	 	 	 	Its:	 

 

 

     IN WITNESS WHEREOF, the parties hereto have caused this Support Agreement to be duly executed
as of the date first above written.

	 	 	 	 	 	 	 	 	 
	“Parent”	 	 	 	“Stockholder”
	 
	 	 	 	 	 	 	 	 
	Emergent BioSolutions Inc.	 	 	 	Venrock Partners, L.P.
	 
	 	 	 	 	 	By:	 	Venrock Partners Management LLC,
	 
	 	 	 	 	 	 	 	Its: General Partner
	By:
	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 
	 
	 	Name:	 	 	 	 	 	 
	 	 	Its:	 	 	 	Venrock Associates IV, L.P.
	 
	 	 	 	 	 	By:	 	Venrock Management IV, LLC,
	 
	 	 	 	 	 	 	 	Its: General Partner
	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Venrock Entrepreneurs Fund IV, L.P.
	 
	 	 	 	 	 	By:	 	VEF Management IV, LLC,
	 
	 	 	 	 	 	 	 	Its: General Partner
	 
	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	By:	 	 
	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	Name: David L. Stepp
	 
	 	 	 	 	 	 	 	Its:                    Authorized Signatory

 

 

     IN WITNESS WHEREOF, the parties hereto have caused this Support Agreement to be duly executed
as of the date first above written.

	 	 	 	 	 	 	 	 	 	 
	“Parent”	 	 	 	“Stockholder”	
	 
	 	 	 	 	 	 	 	 	
	Emergent BioSolutions Inc.	 	 	 	Prospect Venture Partners II, L.P.	
	 
	 	 	 	 	 	By:	 	Prospect Management Co. II, LLC	
	 
	 	 	 	 	 	 	 	General Partner	
	By:
	 	 	 	 	 	 	 	 	
	 
	 	 	 	 	 	 	 	
	 
	 	Name:	 	 	 	 	 	 	
	 
	 	Its:	 	 	 	By:	 	 	
	 
	 	 	 	 	 	 	 	
	 
	 		 	 	 	 	 	Name: David Markland	
	 
	 	 	 	 	 	 	 	Its:                   Attorney-In-Fact	
	 
	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	Prospect Associates II, L.P.	
	 
	 	 	 	 	 	By:	 	Prospect Management Co. II, LLC	
	 
	 	 	 	 	 	 	 	General Partner	
	 
	 	 	 	 	 	 	 	 	
	 
	 	 	 	 	 	By:	 	 	
	 
	 	 	 	 	 	 	 	
	 
	 	 	 	 	 	 	 	Name: David Markland	
	 
	 	 	 	 	 	 	 	Its:                   Attorney-In-Fact	
	_
	 	 	 	 	 	 	 	 	

 

 

Annex A

	 	 	 	 	 
	 	 	 	 	C
	A	 	B	 	Shares subject to
	Stockholder	 	Shares Owned	 	this Agreement
	ARCH Venture Fund V, L.P.
	 	2,209,741	 	1,900,377
	ARCH V Entrepreneurs Fund, L.P.
	 	14,503	 	12,473
	Healthcare Focus Fund, L.P.
	 	132,802	 	114,210
	TOTAL
	 	2,357,046	 	2,027,060

Notice to:

ARCH Venture Partners

8725 W. Higgins Road, Suite 290

Chicago, IL 60631

Attn: Mark McDonnell

Facsimile: (773) 380-6606

 

 

Annex A

	 	 	 	 	 
	 	 	 	 	C
	A	 	B	 	Shares subject to
	Stockholder	 	Shares Owned	 	this Agreement
	Frazier Healthcare IV, LP
	 	1,632,687	 	1,404,111
	Frazier Affiliates IV, LP
	 	8,291	 	7,130
	Frazier Healthcare III, LP
	 	592,505	 	509,554
	Frazier Affiliates III, LP
	 	4,457	 	3,833
	TOTAL
	 	2,237,940	 	1,924,628

Notice to:

Frazier Healthcare

601 Union Street, Suite 3300

Two Union Square

Seattle, WA 98101

Attn: Patrick Heron

Facsimile: (206) 621-1848

 

 

Annex A

	 	 	 	 	 
	 	 	 	 	C
	A	 	B	 	Shares subject to
	Stockholder	 	Shares Owned	 	this Agreement
	Venrock Associates IV, L.P.
	 	1,512,111	 	1,300,415
	Venrock Partners, L.P.
	 	308,367	 	265,196
	Venrock Entrepreneurs Fund IV, L.P.
	 	37,154	 	31,953
	TOTAL
	 	1,857,632	 	1,597,564

Notice to:

Venrock

3340 Hillview Avenue

Palo Alto, CA 94304

Attn: David Stepp

Facsimile: (650) 561-9180

 

 

Annex A

	 	 	 	 	 
	 	 	 	 	C
	A	 	B	 	Shares subject to
	Stockholder	 	Shares Owned	 	this Agreement
	Prospect Venture Partners II, LP
	 	1,829,765	 	1,573,598
	Prospect Associates II, LP
	 	27,866	 	23,965
	TOTAL
	 	1,857,631	 	1,597,563

Notice to:

Prospect Venture Partners

435 Tasso Street, Suite 200

Palo Alto, CA 94301

Attn: Dave Markland

Facsimile: (650) 324-8838

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}]]